MRI, Mammography Outperform Whole Breast Ultrasound for Dense Breasts
By Elana Gotkine HealthDay Reporter
THURSDAY, May 29, 2025 -- Abbreviated magnetic resonance imaging (MRI) and contrast-enhanced mammography detect more cancers and invasive cancers than automated whole breast ultrasound (ABUS), according to a study published online May 21 in The Lancet.
Fiona J. Gilbert, M.B.Ch.B., from the University of Cambridge in the United Kingdom, and colleagues conducted a randomized controlled trial at 10 breast screening sites involving women aged 50 to 70 years with dense breasts and negative mammogram who were independently allocated to receive abbreviated MRI (2,318 women), ABUS (2,240), or contrast-enhanced mammography (2,235) or standard of care (2,568). The outcome analysis included 2,130 women in the abbreviated MRI group, 2,141 in the ABUS group, and 2,035 in the contrast-enhanced mammography group.
The researchers found that the cancer detection rate was 17.4, 4.2, and 19.2 per 1,000 examinations for abbreviated MRI, ABUS, and contrast-enhanced mammography, respectively, of which 15.0, 4.2, and 15.7 per 1,000 examinations, respectively, were for invasive cancers. The detection rates were significantly higher for abbreviated MRI than for ABUS and nonsignificantly higher for abbreviated MRI than for contrast-enhanced mammography.
"This study shows that contrast-enhanced techniques such as abbreviated MRI and contrast-enhanced mammography have a superior performance compared with whole breast ultrasound," the authors write.
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
ASCO: Vepdegestrant Ups Survival in ER+, HER2− Advanced Breast Cancer With ESR1 Mutations
MONDAY, June 2, 2025 -- For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, the oral...
Culturally Tailored Intervention Beneficial for Latina Breast Cancer Survivors
MONDAY, June 2, 2025 -- A culturally tailored intervention for Latina breast cancer survivors (BCSs) yields clinically relevant but not statistically significant improvement in...
ASCO: AI Training Improves Accuracy of HER2 Immunohistochemistry Scoring
FRIDAY, May 30, 2025 -- Artificial intelligence (AI)-assisted training improves pathologist accuracy in human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.